Genmab | GEN - PE Price to Earnings


Genmab reported 17.14 in PE Price to Earnings for its fiscal quarter ending in December of 2025.





Pe Change Date
Agios Pharmaceuticals 3.56 0 Mar/2026
Almirall 79.43 0.3 Dec/2025
Amarin 91.05 88.3 Jun/2023
Amgen 19.84 5.47 Mar/2026
argenx SE 32.12 10.9 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Bayer 3.4 8.75 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Demant 27.46 7.1 Dec/2025
Exelixis 13.91 588.4 Mar/2026
Fresenius Medical Care 6.64 2.07 Mar/2026
Genmab 17.14 4.39 Dec/2025
GlaxoSmithKline 14.87 3.72 Mar/2026
GN Store Nord 10.77 12.24 Mar/2026
GRIFOLS 10.98 5.83 Mar/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
Lakefront Biotherapeutics 2.54 0.6 Mar/2026
Lonza 34.34 2.58 Dec/2025
Merck 12.74 7.82 Mar/2026
Novartis 20.17 2.32 Mar/2026
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
UCB 29.7 5.52 Dec/2025